


NEW CRYSTALLINE FORM VI OF AGOMELATINE, PREPARATION METHOD AND APPLICATION THEREOF

Technical field

The invention relates to a crystalline form of agomelatine, N-[2-(7-methoxy-1-naphthyl)]acetamide, its preparation and use thereof.

Technical Background

Agomelatine with chemical name N-[2-(7-methoxy-1-naphthyl)ethyl]acetamide and brand name Valdoxan has the following formula:



Agomelatine has dual effects by acting as an agonist of melatonergic system receptors and as an antagonist of the 5HT_{2C} receptor. Its properties allow it to be active in the central nervous system, especially in the treatment of major depression, seasonal affective disorder, sleep disorder, cardiovascular diseases, diseases of the digestive system, insomnia and fatigue caused by jet lag, appetite disturbance and obesity. Agomelatine is the first melatonergic antidepressant, and is effective for the treatment of depression, the improvement of sleep parameters and the maintenance of sexual function. The preparation and therapeutic use of agomelatine have been reported in the European patent EP0447285.

In view of the pharmaceutical value of agomelatine, it is critical to obtain the said compound in a highly pure, and stable crystalline form as well as with good reproducibility so that it will be advantageous in pharmaceutical formulations and stable enough for long-term storage without specific requirements regarding temperature, light, humidity or oxygen levels.

Chinese Patents CN200510071611.6, CN200610108396.7, CN200610108394.8 and CN200610108395.2 have respectively disclosed the crystalline forms II, III, IV, V of agomelatine and the preparations thereof.

Among these, crystalline form II is prepared by recrystallization from ethanol and water; crystalline form III is prepared by heating agomelatine at 110°C until complete melting occurs and then slowly cooling down until formation of the crystal; crystalline form IV is prepared by heating agomelatine at 110°C until complete melting occurs, followed by rapidly cooling down to 50-70°C and maintaining at 70°C for about 5h until formation of the crystal occurs; crystalline form V is prepared by so-called “high-energy” mechanical grinding of agomelatine.

Description of the Invention

An objective of the invention is to provide a new crystalline form of agomelatine, i.e. crystalline form VI, which exhibits valuable characteristics in the pharmaceutical formulation.

Another objective of the invention is to provide a process for preparing crystalline form VI of agomelatine, which is simple to implement and easily reproducible.

The crystalline form of agomelatine, wherein the X-ray powder diffraction diagram of the crystalline form of agomelatine shows main peaks at the diffraction angles 2θ 11.13°, 11.82°, 17.49°, 18.29°, 19.48°, 19.72°, 20.50°, 21.76°, 22.54°, 22.97°, 24.56°, 25.36°, 27.16° and 31.93°.

The crystalline form of agomelatine, wherein the main peaks at the diffraction angles 2θ in the X-ray powder diffraction diagram of the crystalline form of agomelatine shows the following relative intensity (in percentages):

$2\theta^\circ$	Relative Intensity
11.13	12.4
11.82	17.8
17.49	20.7
18.29	17.9

19.48	66.8
19.72	100
20.50	14.5
21.76	19.7
22.54	22.0
22.97	26.2
24.56	13.1
25.36	16.7
27.16	12.2
31.93	10.1

A process for preparing the crystalline form of agomelatine, wherein agomelatine is firstly dissolved in acetic acid and then added into 0-25°C water to precipitate the crystal.

The process for preparing the crystalline form of agomelatine above, wherein the solution of agomelatine in acetic acid is most preferably added slowly to water with continuous stirring to facilitate the precipitation of the crystal. The said gradual addition to water may be achieved by dropwise addition.

The pharmacological studies with crystalline form VI of agomelatine according to the invention showed that the crystalline form VI of agomelatine may be used in the treatment of diseases of the melatoninergetic system, sleep disorder, stress, anxiety, seasonal affective disorder or major depression, cardiovascular diseases, diseases of the digestive system, insomnia and fatigue caused by jet lag, schizophrenia, phobia, depression and the like.

The crystalline form VI of agomelatine provided according to the invention may be formulated together with various pharmaceutically acceptable adjuvants or excipients as various dosage forms for oral or injection administration.

According to the invention, the new crystalline form VI is obtained with high purity, stability and good reproducibility, and is advantageous for the pharmaceutical formulation. In addition, the stability and solubility of said crystalline form are also superior over the several existing crystalline forms.

Brief Description of the Drawing

Fig.1 is an X-ray diffraction diagram of the crystalline form VI obtained from Example 1 of the invention, measured by Bruker D8 ADVANCE instrument under the following settings: Cuka 40Kv 40mA as light source, step length 0.02°, scan speed: 8°/min, scan range: 3°-80°, room temperature.

Specific Embodiments

Example 1

1g of agomelatine was dissolved in 4ml of acetic acid with stirring, then slowly added dropwise to 80ml of water. The mixture was maintained at 0°C with stirring for 3.5h and filtered. The solid was washed with water 8ml×2, dried at 55°C under vacuum until the weight was constant to give 0.91g of white solid. Purity: 99.6%, melting point: 97-98°C.

Example 2

1g of agomelatine was dissolved in 4ml of acetic acid with stirring, then slowly added dropwise to 80ml of water. The mixture was maintained at 5°C with stirring for 3h and filtered. The solid was washed with water 8ml×2, dried at 55°C under vacuum until the weight was constant to give 0.90g of white solid. Purity: 99.6%, melting point: 97-98°C.

Example 3

2g of agomelatine was dissolved in 8ml of acetic acid with stirring, then slowly added dropwise to 160ml of water. The mixture was maintained at 20°C with stirring for 3h and filtered. The solid was washed with water 16ml×2, dried at 55°C under vacuum until the weight was constant to give 1.76g of white solid. Purity: 99.6%, melting point: 97-98°C.

The crystalline form of agomelatine from Example 2 was dried to give a powdery product, whose X-ray diffraction diagram was plotted with interplanar spacing d , Bragg 2θ angle and relative intensity as follows:

$2\theta^\circ$	$d(\text{\AA})$	Relative Intensity
11.13	7.942	12.4
11.82	7.481	17.8
17.49	5.066	20.7
18.29	4.846	17.9
19.48	4.553	66.8
19.72	4.498	100
20.50	4.328	14.5
21.76	4.080	19.7
22.54	3.941	22.0
22.97	3.868	26.2
24.56	3.621	13.1
25.36	3.509	16.7
27.16	3.280	12.2
31.93	2.800	10.1

Tests of experimental results

Crystalline forms II, III, IV and VI are respectively placed in a thermostatically controlled container at 40°C for 20 days. The stability of the said crystalline forms is assessed by high performance liquid chromatography.

1. Purity Measurement of the Sample

Chromatographic conditions: octadecylsilane bonded silica as filler; a mixed solution of 10mM/L phosphate buffer (adjusted to pH 7.0 by sodium hydroxide) and acetonitrile in 2:7 by volume as mobile phase; column temperature 40°C; detection wavelength 220nm. The purity is determined using an internal standard method.

The crystalline forms II, III, IV and VI were formulated with the mobile phase as 1mg/mL solution. 10µL of each of the solution was removed and injected into the liquid chromatograph. The chromatograms were recorded.

2. Assay of the Sample

The assay was carried out using an external standard method as described under Purity Measurement of the Sample. The results are as shown in Table I:

Table I

Sample name	Purity of crystalline form II	Purity of crystalline form III	Purity of crystalline form IV	Purity of crystalline form VI
Before storage	99.79%	99.77%	99.82%	99.60%
After storage in the thermostatically controlled containers for 20 days	99.24%	99.10%	99.54%	99.55%

3. Solubility Measurement in Water

The measurement was carried out by HPLC using an external standard method. The results are as shown in Table II:

Table II

Sample name	Purity of crystalline form II	Purity of crystalline form VI
Purity	99.79%	99.77%
Solubility (mg/ml)	1.11	1.24

From the above results, it is seen that the new crystalline form VI of agomelatine is superior over the several existing crystalline forms in terms of stability and solubility. With regard to its preparation, the new crystalline form is also of greater value than the existing crystalline forms III, IV and V in terms of industrial application.

The claims defining the invention are as follows:

1. A crystalline form of agomelatine, wherein the X-ray powder diffraction diagram of the crystalline form of agomelatine shows main peaks at the diffraction angles 2θ 11.13°, 11.82°, 17.49°, 18.29°, 19.48°, 19.72°, 20.50°, 21.76°, 22.54°, 22.97°, 24.56°,
5 25.36°, 27.16° and 31.93°.
2. The crystalline form of agomelatine according to claim 1, wherein the main peaks at the diffraction angles 2θ in the X-ray powder diffraction diagram of the crystalline form of agomelatine show the following relative intensities (in percentages):

$2\theta^\circ$	Relative Intensity (%)
11.13	12.4
11.82	17.8
17.49	20.7
18.29	17.9
19.48	66.8
19.72	100
20.50	14.5
21.76	19.7
22.54	22.0
22.97	26.2
24.56	13.1
25.36	16.7
27.16	12.2
31.93	10.1

3. A process for preparing the crystalline form of agomelatine according to claim 1 or 2, wherein agomelatine is first dissolved in acetic acid and then added into 0-25°C water to precipitate the crystal.
4. The process according to claim 3, wherein the solution of agomelatine in acetic acid is added slowly to water with continuous stirring to facilitate the precipitation of the crystal.
5. A process for preparing crystalline form VI of agomelatine, substantially as hereinbefore described with reference to any one of Examples 1-3.
6. A pharmaceutical composition, comprising the crystalline form VI of agomelatine according to claim 1 or 2, optionally together with one or more pharmaceutically acceptable adjuvants or excipients.
7. Crystalline form VI of agomelatine according to claim 1 or 2 for use in the treatment of diseases of the melatoninerpic system, sleep disorder, stress, anxiety, seasonal affective disorder or major depression, cardiovascular diseases, diseases of the digestive system, insomnia and fatigue caused by jet lag, schizophrenia, phobia, depression and the like.
8. A method for the treatment of diseases of the melatoninerpic system, sleep disorder, stress, anxiety, seasonal affective disorder or major depression, cardiovascular diseases, diseases of the digestive system, insomnia and fatigue caused by jet lag, schizophrenia, phobia, depression and the like, the method comprising administering to a mammal in need of such treatment an effective amount of crystalline form VI of agomelatine according to claim 1 or 2, or the pharmaceutical composition according to claim 6.
9. Use of crystalline form VI of agomelatine according to claim 1 or 2 in the manufacture of a medicament for the treatment of diseases of the melatoninerpic system, sleep disorder, stress, anxiety, seasonal affective disorder or major depression, cardiovascular diseases, diseases of the digestive system, insomnia and fatigue caused by jet lag, schizophrenia, phobia, depression and the like.